News & Events

News

Our latest Press Releases

Tubulis Announces Second Closing of Series C Bringing Total Raised to €344M (US $401M)

Tubulis Presents First Clinical Data from Phase I/IIa Trial for TUB-040 in Platinum-Resistant Ovarian Cancer (PROC) at ESMO 2025

Tubulis Raises €308 Million Series C to Accelerate Clinical Development of Lead ADC Candidate TUB-040 and Expand Pipeline

EVENTS

Meet Tubulis live